KRAS G12C inhibition using MRTX849: A novel radiosensitizing partner

被引：0
|
作者：
Milic, M. [1 ]
Laurent, P-A. [2 ]
Quevrin, C. [2 ]
Meziani, L. [3 ]
Morel, D. [4 ]
Signolle, N. [5 ]
Clemenson, C. [6 ]
Levy, A. [7 ]
Mondini, M. [6 ]
Deutsch, E. [8 ]
机构：
[1] Inst Gustave Roussy, Oncol Dept, Villejuif, France
[2] Inst Gustave Roussy, Radiotherapy Dept, Villejuif, France
[3] Inst Gustave Roussy, INSERMU1030, Villejuif, France
[4] Inst Gustave Roussy, Expt & Translat Pathol Platform, Villejuif, France
[5] Gustave Roussy Canc Campus, Pathol, Villejuif, France
[6] Inst Gustave Roussy, INSERM U1030, Villejuif, France
[7] Gustave Roussy Canc Campus, Radiat Oncol Dept, Villejuif, France
[8] Inst Gustave Roussy, Radiat Oncol, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2252P
引用
收藏
页码：S1159 / S1159
页数：1
相关论文
共 50 条
  • [1] The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models
    Hallin, Jill
    Calinisan, Andrew
    Hargis, Lauren
    Aranda, Ruth
    Engstrom, Lars D.
    Briere, David M.
    Marx, Matthew A.
    Olson, Peter
    Christensen, James G.
    CANCER RESEARCH, 2020, 80 (16)
  • [2] A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
    Papadopoulos, Kyriakos P.
    Ou, Sai-Hong Ignatius
    Johnson, Melissa Lynne
    Christensen, James
    Velastegui, Karen
    Potvin, Diane
    Faltaos, Demiana
    Chao, Richard C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
    Spira, A.
    Riely, G.
    Lawler, W.
    Shum, M.
    Socinski, M.
    Yanagihara, R.
    Roshan, S.
    Kheoh, T.
    Christensen, J.
    Chao, R.
    Janne, P.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S696
  • [4] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
    Johnson, M. L.
    Ou, S. H. I.
    Barve, M.
    Rybkin, I. I.
    Papadopoulos, K. P.
    Leal, T. A.
    Velastegui, K.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Weiss, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S2 - S2
  • [5] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
    Janne, P. A.
    Rybkin, I. I.
    Spira, A. I.
    Riely, G. J.
    Papadopoulos, K. P.
    Sabari, J. K.
    Johnson, M. L.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Leal, T. A.
    Velastegui, K.
    Cornelius, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Ou, S. H. I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S2
  • [6] KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
    Sabari, Joshua K.
    Park, Haeseong
    Tolcher, Anthony W.
    Ou, Sai-Hong Ignatius
    Garon, Edward B.
    George, Ben
    Janne, Pasi A.
    Moody, Susan Elizabeth
    Tan, Eugene Y.
    Sen, Suman Kumar
    Peters, Dana
    Yan, Xiaohong
    Christensen, James G.
    Chi, Andrew S.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers
    Christensen, James G.
    Fell, Jay B.
    Hallin, Jill
    Baer, Brian
    Engstrom, Lars
    Blake, James
    Briere, David
    Ballard, Josh
    Burkhard, Michael
    Fischer, John
    Vigers, Guy
    Aranda, Ruth
    Bowcut, Vickie
    Calinisan, Andrew
    Hargis, Lauren
    Sudhakar, Niranjan
    Marx, Matt
    Olson, Peter
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [8] Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
    Woodcock, M.
    Tsai, Y. S.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    Vincent, B. G.
    Pecot, C. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S599 - S600
  • [9] KRAS G12C inhibition and innate immune targeting
    Tani, Tetsuo
    Kitajima, Shunsuke
    Conway, Ella B.
    Knelson, Erik H.
    Barbie, David A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (03) : 167 - 174
  • [10] SHP2 Contributes to Resistance of KRAS p.G12C-Driven Lung Cancer Cells to MRTX849 by Regulating β-catenin/c-MYC Axis
    Li, Wenli
    Wu, Ya
    Dai, Lili
    Wang, Wei
    Zhao, Lei
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2023, 53 (04): : 630 - 640
12345